INKT

MiNK Therapeutics, Inc. [INKT] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

INKT Stock Summary

Top 10 Correlated ETFs

INKT

Top 10 Correlated Stocks

INKT

In the News

INKT Financial details

Company Rating
-
Market Cap
34.17M
Income
145.76M
Revenue
11.71B
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
31
Optionable
No
Shortable
Yes
Earnings
11 May 2024
P/E
0.24
Forward P/E
-
PEG
-0
P/S
-
P/B
-2.57
P/C
-
P/FCF
-2.01
Quick Ratio
0.62
Current Ratio
0.62
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
4.3
EPS next Y
-
EPS next Q
-
EPS this Y
-12.16%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-3.58%
Revenue last 5Y
-100%
Revenue Q/Q
-
EPS Q/Q
6.67%
-
-
-
-
SMA20
-
SMA50
-20%
SMA100
14.29%
Inst Own
-
Inst Trans
-
ROA
1926%
ROE
-2057%
ROC
8.63%
Gross Margin
-21%
Oper. Margin
-
Profit Margin
1%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.75-3.34
52W High
-
52W Low
-
RSI
41
Rel Volume
0.02
Avg Volume
104.3K
Volume
2.11K
Perf Week
-4.22%
Perf Month
-5.22%
Perf Quarter
2.4%
Perf Half Y
6.3%
-
-
-
-
Beta
0.123
-
-
Volatility
0.37%, 0.58%
Prev Close
0.14%
Price
7.26
Change
-4.35%

Something similar

Top by Market Cap
FXAIX
NVDA
NVD.DE
AVGO
BRH.DE
Top Correlated ETFs
XBAK.DE
MSAP.L
IUSW.DE
PULT
IUSS.DE
Top Correlated Stocks
AUBN
CER.L
AURA.L
DSG.L
GWMO.L
Similar Market Cap
UNOV
YELL
MANTEX.ST
ACACU
8009.HK

Company Profile

Healthcare Biotechnology
  • Volume Average 104.3K
  • Market Capitalization 34.17M
  • Employee 31
  • CEO Dr. Jennifer S. Buell Ph.D.
  • Headquarters New York,NY,US
  • IPO Date 2021-10-15
  • Website https://minktherapeutics.com

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.